Korea’s Celltrion Prepares Remicade Biosimilar Application For KFDA
This article was originally published in PharmAsia News
Executive Summary
Korea’s biosimilar frontrunner Celltrion is only one step away from the actual sales of its first biosimilar as it gears up to file for KFDA approval in February for its biosimilar of Johnson & Johnson’s rheumatoid arthritis agent Remicade.